当前位置: 首页 >> 检索结果
125. Epidemiology of Coronary Atherosclerosis Among People Living With HIV in Uganda : A Cross-Sectional Study.
作者: Mark J Siedner.;Brian Ghoshhajra.;Geoffrey Erem.;Rita Nassanga.;Mangun Randhawa.;Andrew Ochieng.;Moses Acan.;Michael T Lu.;Vikas Thondapu.;Angelo Takigami.;Zahra Reynolds.;Flavia Atwiine.;Edna Tindimwebwa.;Rebecca F Gilbert.;Eliza Passell.;Shruti Sagar.;Yao Tong.;Ntobeko A B Ntusi.;Alexander C Tsai.;Prossy Bibangambah.;Thomas Gaziano.;Susanne S Hoeppner.;Christopher T Longenecker.;Samson Okello.;Stephen Asiimwe.
来源: Ann Intern Med. 2025年178卷4期468-478页
Data on the prevalence of coronary atherosclerotic disease (CAD) in the African region among people with and without HIV are lacking.
126. Health Care Delivery of Clinical Preventive Services for People With Disabilities : A Systematic Review.
作者: David I Buckley.;Frances Hsu.;Tracy Dana.;Keeley Blackie.;Rebecca Holmes.;Peggy Nygren.;Willi Horner-Johnson.;Christina Nicolaidis.;Roger Chou.
来源: Ann Intern Med. 2025年
People with disabilities are less likely than the general population to receive clinical preventive services.
127. Gout.
Gout is characterized by deposition of monosodium urate (MSU) crystals in or around joints, tendons, bursae, and other tissues, resulting in painful recurrent flares and tissue damage. Gout is the most common form of inflammatory arthritis, with a prevalence of 5.1% in the United States, affecting 12.1 million adults. When urate levels exceed the limit of solubility (6.8 mg/dL [400 μmol/L]), MSU crystals may form or grow. Gout flares are the result of inflammatory responses to MSU crystals. The primary method to prevent and reduce gout flares, tophi, chronic inflammatory arthritis, and joint damage is to reduce urate levels below the saturation threshold. The pathophysiology of gout is well understood, and inexpensive and effective therapies are available. However, outcomes for patients with gout remain poorly optimized.
130. Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline.
作者: Magdalena Madero.;Adeera Levin.;Sofia B Ahmed.;Juan Jesus Carrero.;Bethany Foster.;Anna Francis.;Rasheeda K Hall.;William G Herrington.;Guy Hill.;Lesley A Inker.;Rümeyza Kazancıoğlu.;Edmund Lamb.;Peter Lin.;Natasha McIntyre.;Kelly Morrow.;Glenda Roberts.;Dharshana Sabanayagam.;Michael Shlipak.;Rukshana Shroff.;Navdeep Tangri.;Teerawat Thanachayanont.;Ifeoma Ulasi.;Germaine Wong.;Chih-Wei Yang.;Luxia Zhang.;Karen A Robinson.;Lisa M Wilson.;Renee F Wilson.;Bertram L Kasiske.;Michael Cheung.;Amy Earley.;Paul E Stevens.;Elke Schaeffner.
来源: Ann Intern Med. 2025年
The Kidney Disease: Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 to provide guidance on the evaluation, management, and treatment of chronic kidney disease (CKD) in adults and children who are not receiving kidney replacement therapy.
135. In previous MI with ventricular tachycardia (VT), catheter ablation reduced mortality or VT events more than antiarrhythmic drug therapy at 4 y.
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].
136. In symptomatic severe tricuspid regurgitation, adding TTVR to medical therapy improved a hierarchical composite outcome at 1 y.
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].
|